Clinical Trials/NCT00162318

NCT00162318

Completed

Phase 1

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Eli Lilly and Company1 site in 1 country30 target enrollmentMarch 2005

ConditionsNon-Small-Cell Lung Carcinoma

InterventionsCetuximab + Gefitinib

DrugsCetuximab + Gefitinib

Overview

Phase: Phase 1
Intervention: Cetuximab + Gefitinib
Conditions: Non-Small-Cell Lung Carcinoma
Sponsor: Eli Lilly and Company
Enrollment: 30
Locations: 1
Primary Endpoint: Safe and effective dose of combination of Erbitux and Iressa therapy.
Status: Completed
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.

Registry

clinicaltrials.gov

Start Date

March 2005

End Date

April 2006

Last Updated

10 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Eli Lilly and Company

Eligibility Criteria

Inclusion Criteria

•Subjects with advanced or metastatic non small cell lung cancer.
•Subjects should have had at least one prior chemotherapy with a platinum based therapy.

Exclusion Criteria

•Subjects are excluded from this study if they do not have non small cell lung cancer that is advanced or metastatic or have not had at least one prior platinum based chemotherapy.

Arms & Interventions

A

Intervention: Cetuximab + Gefitinib

Outcomes

Primary Outcomes

Safe and effective dose of combination of Erbitux and Iressa therapy.

Secondary Outcomes

Response will be measured by radiographic measurement of disease every 4 weeks.

Study Sites (1)

Loading locations...

Similar Trials

Study of Cetuximab in Combination With Tarceva in Patients With Solid TumorsNeoplasms

NCT00207077Eli Lilly and Company33

Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic CancerPancreatic Cancer

NCT00225784Dartmouth-Hitchcock Medical Center37

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7

NCT01935921National Cancer Institute (NCI)19

Palbociclib and Cetuximab in Metastatic Colorectal CancerCancer of the ColonColon CancerColon NeoplasmsColonic CancerNeoplasms, Colonic

NCT03446157UNC Lineberger Comprehensive Cancer Center24

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma

NCT00409565National Cancer Institute (NCI)48